Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 5/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SCN4A | P35499 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 2/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610771 | 0.79 | COMT (0.43) | COMTLRRK2MAPTSCN4APOLB | |
| SCHEMBL7610118 | 0.75 | COMT (0.41) | COMTLRRK2MAPTSCN4APOLB | |
| SCHEMBL7609894 | 0.75 | COMT (0.37) | COMTLRRK2MAPTSCN4APOLB | |
| SCHEMBL6738532 | 0.73 | SMN1; SMN2 (0.41) | COMTLRRK2MAPTPOLBNPC1 | |
| SCHEMBL6933828 | 0.69 | COMT (0.34) | COMTLRRK2MAPTSCN4APOLB | |
| SCHEMBL6736429 | 0.66 | ALDH1A1 (0.35) | MAPTPOLBNPC1ALDH1A1RAB9A | |
| SCHEMBL3068150 | 0.61 | SCN4A (0.62) | COMTSCN4APOLBNPC1ALDH1A1 | |
| SCHEMBL863096 | 0.58 | COMT (0.49) | COMTMAPTSCN4APOLBNPC1 | |
| SCHEMBL14213215 | 0.58 | COMT (0.44) | COMTMAPTSCN4APOLBNPC1 | |
| SCHEMBL10311042 | 0.57 | POLB (0.57) | MAPTSCN4APOLBNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020031536-A1 | Cosmetic compositions based on 4,5-pyrazolinediones, novel 4,5-pyrazolinediones, process for their preparation and uses thereof | L'OREAL SA | 2002-03-14 | — | — | US | disclosed |
| US-6322775-B1 | FOR COLORING THE SKIN AND/OR THE HAIR; SIDE EFFECTS REDUCTION; STABILITY | L'OREAL S.A. (FR) | 2001-11-27 | — | — | US | disclosed |
| EP-0888306-B1 | COSMETIC COMPOSITIONS CONTAINING PYRAZOLIN-4,5-DIONES, NOVEL PYRAZOLIN-4,5-DIONES, PREPARATION METHODS THEREFOR AND USES THEREOF | OREAL (FR) | 2001-07-25 | — | — | EP | disclosed |
| EP-0888306-A1 | COSMETIC COMPOSITIONS CONTAINING PYRAZOLIN-4,5-DIONES, NOVEL PYRAZOLIN-4,5-DIONES, PREPARATION METHODS THEREFOR AND USES THEREOF | L'OREAL (FR) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997035842-A1 | COSMETIC COMPOSITIONS CONTAINING PYRAZOLIN-4,5-DIONES, NOVEL PYRAZOLIN-4,5-DIONES, PREPARATION METHODS THEREFOR AND USES THEREOF | L'OREAL (FR) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020031536-A1 | Cosmetic compositions based on 4,5-pyrazolinediones, novel 4,5-pyrazolinediones, process for their preparation and uses thereof | PPARD, PLIN5, PDK4 | COMT 4267/4885LRRK2 3897/4885MAPT 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.